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Abstract
Monitoring the efficacy of novel reservoir-reducing treatments for HIV is challenging. The
limited ability to sample and quantify latent infection means that supervised antiretroviral
therapy (ART) interruption studies are generally required. Here we introduce a set of mathe-
matical and statistical modeling tools to aid in the design and interpretation of ART-interrup-
tion trials. We show how the likely size of the remaining reservoir can be updated in real-
time as patients continue off treatment, by combining the output of laboratory assays with
insights from models of reservoir dynamics and rebound. We design an optimal schedule
for viral load sampling during interruption, whereby the frequency of follow-up can be
decreased as patients continue off ART without rebound. While this scheme can minimize
costs when the chance of rebound between visits is low, we find that the reservoir will be
almost completely reseeded before rebound is detected unless sampling occurs at least
every two weeks and the most sensitive viral load assays are used. We use simulated data
to predict the clinical trial size needed to estimate treatment effects in the face of highly vari-
able patient outcomes and imperfect reservoir assays. Our findings suggest that large num-
bers of patients—between 40 and 150—will be necessary to reliably estimate the reservoir-
reducing potential of a new therapy and to compare this across interventions. As an exam-
ple, we apply these methods to the two “Boston patients”, recipients of allogeneic hemato-
poietic stem cell transplants who experienced large reductions in latent infection and
underwent ART-interruption. We argue that the timing of viral rebound was not particularly
surprising given the information available before treatment cessation. Additionally, we show
how other clinical data can be used to estimate the relative contribution that remaining
HIV+ cells in the recipient versus newly infected cells from the donor made to the residual
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reservoir that eventually caused rebound. Together, these tools will aid HIV researchers in
the evaluating new potentially-curative strategies that target the latent reservoir.
Author Summary
New therapies are being developed to permanently cure HIV infection. Many aim to
reduce the pool of latent virus that persists despite years of treatment with antiretroviral
drugs. Because latent virus is so difficult to sample and measure, often the only way to
know if these new therapies have worked is to interrupt all treatment, and wait indefinitely
to see if the infection rebounds. In this study we use a set of mathematical and statistical
models to suggest optimal ways to design and interpret these treatment interruption trials.
For various scenarios, we predict how long patients should be followed to be confident
that they are cured, how frequent viral load sampling should occur, and how large clinical
trials will need to be to estimate and compare drug efficacy. We demonstrate how to infer
a range for number of remaining latent cells based on the timing of rebound after a long
remission. As a case study, we apply these results to data from two HIV-positive patients
who underwent bone marrow transplants and remained off treatment for months before
suddenly rebounding. These findings can help inform the testing of new potentially-cura-
tive HIV therapies.
Introduction
Twenty years after the introduction of combination antiretroviral therapy (cART) for HIV
infection, the search continues for a cure, an intervention that would allow infected individuals
to discontinue all treatments without experiencing viral rebound. One promising approach
to achieve a cure is to eradicate latent virus that remains in resting CD4+ T cells despite long-
term cART [1]. Pharmacologic agents that reactivate viral gene expression, collectively called
latency-reversing agents (LRA), are undergoing preliminary clinical evaluation [2–4]. A major
unknown regarding the potential efficacy and safety of LRAs is how much the latent reservoir
(LR) must be reduced in order to delay or prevent viral rebound following cART interruption.
Answering this question is an important prerequisite for initiating or scaling up clinical trials.
For example, should a compound that reactivates 90% of latently infected cells in vitro be
moved into clinical trials, or would this compound provide insufficient benefit relative to the
risk of interrupting cART? What if it’s 99%?
Case reports of patients who achieved reduction in the latent reservoir by different means
give some guidance. A greater than 3.5 log-reduction in the “Berlin patient,” in the setting of the
Δ 32 CCR5 mutation, has lead to a cART-free period without viral rebound that is now 8 years
in length [5]. At least 2 log-reductions in two hematopoietic stem-cell transplant recipients, the
“Boston patients,” resulted in cART-free remissions of 3 and 8 months before viral rebound [6,
7]. An early-treated neonate, the “Mississippi baby,” achieved an LR size at least 2.5 logs smaller
than the typical adult size and experienced rebound after 27 months [8]. An early treatment ini-
tiation case with LR size 3 logs below the typical size rebounded after 50 days [9].
We recently developed a mechanistic mathematical model to predict the time to rebound fol-
lowing reservoir reduction [10]. This model describes the relationship between reservoir size
and time to viral rebound, and it predicts large inter-patient variability in response to identical
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treatment regimes. It also suggests that rebound after many months or even years of remission is
a likely outcome, thereby independently predicting the observations of recent case studies [7, 8].
Despite the insight provided by these disparate case studies and mathematical modeling,
there are many open questions about the design and interpretation of trials to assess interven-
tions that reduce the pool of latent virus in HIV-infected individuals. One major challenge is
the limited dynamic range of assays that measure the size of the latent reservoir [11–14]. Con-
sequently, we often do not know the reservoir-reduction induced by the treatment, limiting
our ability to predict outcomes based on previously observed or modeled data.
Absent direct measurement, can we estimate the LR size (and reduction efficacy) immedi-
ately following LRA therapy, based on the mechanism of action of the therapy or other bio-
markers? Can we refine this estimate by observing long-term clinical outcomes of LRA
therapy, in the face of highly variable patient outcomes? Another obstacle is the multi-year fol-
low-up required to confirm that a patient is cured. How often and for how long should viral
load measurements be taken during interruption trials, and can the likelihood of eventual
rebound be updated in real-time as patients continue off treatment?
Many of these uncertainties were highlighted in the recent case of the “Boston patients” [6,
7]. Two HIV+ individuals with lymphoma received allogeneic hematopoietic stem cell trans-
plants (HSCT), after which HIV viral RNA became undetectable by standard clinical assays.
Both patients discontinued cART, and months later they remained HIV-free and were widely
believed to have achieved long-term antiviral-free remission. However, after three and eight
months, both patients experienced spontaneous and rapid viral rebound, suggesting that simi-
lar difficulties are likely to be encountered in future treatment interruption trials. Despite
their impracticality for scale-up, HSCT studies are informative to HIV cure research, because
they offer a model system to test the hypothesis that purging the latent reservoir can prevent
rebound of the infection after interrupting cART. Understanding the likelihood of rebound
and the mechanism of viral persistence in transplant studies is therefore a key facet of HIV
cure research.
Here we present new quantitative approaches for understanding the dynamics of treatment
interruption following reservoir reduction. We extend our mathematical modeling framework
[10] to address the questions raised above, showing how this framework can assist with design-
ing and interpreting outcomes of clinical trials for LRAs. We use clinical and virological data
from the Boston patients as a case study to demonstrate the utility of these methods.
Results
Summary of the model of reservoir dynamics and rebound
Our basic model considers what happens after an LR-reducing therapy is administered and
combination antiretroviral therapy (cART) is interrupted (Fig 1a). It is explained and analyzed
in detail in a separate paper [10]. Briefly, we use a fully stochastic model of infection dynamics
to calculate the probability of achieving a cure or, failing that, the duration of successful treat-
ment interruption before viral rebound occurs, both as functions of the latent reservoir size fol-
lowing an intervention designed to reduce it. For the purpose of the model, this intervention
may be a compound or strategy that reactivates and kills latently infected cells, an allogeneic
hematopoietic stem cell transplant, or any other method of removing latently infected cells.
The model tracks two CD4+ T cell types: productively infected activated cells, and latently
infected resting cells. Latently infected cells can activate, die, or proliferate. Actively infected
cells can produce a burst of virions, resulting in the infection of other cells, or die without pro-
ducing virions. The model is designed to describe only the initial stages of rebound, where viral
loads are well below typical setpoints.
Designing HIV ART-Interruption Trials
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We concluded that model outcomes depend on a small number of parameters, which could
be estimated from existing clinical data [10]. Specifically, the half-life of the pool of latently
infected cells is estimated from studies of LR decay [15, 16], and the activation rate of latent cells
and the viral growth rate can both be estimated from studies of supervised cART interruption
[17, 18]. A fourth parameter, the probability that a single activated cell manages to establish a
growing infection, is less certain and is the subject of both in vitro [19, 20] and population-
genetic research [21–23] (reviewed in [24]).
The model has been used to estimate the relationship between the reservoir size and the pos-
sible outcomes following cART interruption. Here, we measure the reservoir size as the reduc-
tion from to the baseline value of a typical patient, i.e. around 1 infectious unit per million
(IUPM) cells [12, 16]. We call this the reduction efficacy. If a patient begins LRA treatment with
a higher or lower reservoir size than this, the reduction efficacy required to achieve the same
outcome would be correspondingly higher or lower by the same amount. Our analysis is also
relevant to patients in whom initial reservoir seeding was limited, such as during early treatment
initiation. In this case, the reduction efficacy is simply the size of the reservoir relative to that of
the aforementioned “typical” patient (who began cART during chronic infection).
The best outcome of reservoir-reduction, barring complete eradication, is that so few
latently infected cells survive that none successfully reactivate and restart the infection. In this
case, the infection has essentially been cured. If therapy fails to clear the infection, the next-best
outcome is extension of the time until rebound. The results suggested three important findings.
Firstly, reductions of 2 to 3 logs are required to delay rebound for a few months, while> 4-log
reductions may be required for cure in most patients (Fig 1b). Secondly, patients may rebound
even after experiencing several years off treatment without detectable viremia. These late
rebounds pose a challenge for patient management. Thirdly, large inter-patient variation in
times to rebound is expected, meaning that it is very difficult to predict outcomes for any indi-
vidual patient (Fig 1c). This previous work, however, does not address the model’s ability to
inform and interpret clinical trials. Here we show, using the “Boston patients” as case studies,
how this model can be used to provide clinical guidance.
Fig 1. Summary of model of reservoir dynamics and rebound. a) Patients on fully suppressed ART are given an additional intervention to reduce the
LR size. The stochastic model of viral dynamics following ART-interruption tracks both latently infected resting CD4+ T cells (rectangles) and productively
infected CD4+ T cells (ovals). Viral rebound occurs if at least one remaining latently infected cell survives long enough to activate and produce a chain of
infection events leading to detectable viremia. b) Model predictions for probability that the LR is cleared. Clearance occurs if all cells in the LR die before a
reactivating lineage leads to viral rebound. c) Predicted median viral rebound times among patients who do not clear the infection. d) Survival curves
(Kaplan-Meier plots) show the percentage of patients predicted to have not yet experienced viral rebound, as a function of the time after treatment
interruption.
doi:10.1371/journal.ppat.1005535.g001
Designing HIV ART-Interruption Trials
PLOS Pathogens | DOI:10.1371/journal.ppat.1005535 April 27, 2016 4 / 26
Recovering reduction efficacy and LR size based on time of rebound
If the amount by which the LR is reduced is known exactly, then it is possible to predict time to
rebound (Fig 1b). Yet measuring reduction efficacy directly from differences in frequency of
latently infected cells observed before and after therapy may not be practical, due to the limited
dynamic range of current assays and the difficulties in sampling large numbers of T cells from
patients. Here we provide an approach to obtain estimates of reduction efficacy by supplement-
ing the information from latency assays with the information gained by observing a patient’s
rebound time (or absence of rebound). Intuition suggests that the longer a patient has been off
treatment without rebound, the smaller the remaining reservoir size is likely to be. In other
words, even if an investigator has a rough initial estimate of the reduction efficacy of an inter-
vention (based on latency assays), this estimate continually should be revised upward with
each subsequent negative viral load assay over the course of the interruption trial. Formally, we
can use Bayesian updating to estimate the post-reduction reservoir size.
The Bayesian approach to estimate reservoir size requires two inputs: a distribution describ-
ing our knowledge about the reservoir size before the treatment interruption, known as the
prior distribution, and a distribution describing how consistent a given reservoir size is with
the observed rebound time (or the observed period of time without rebound), called the likeli-
hood. The prior can be constructed based on any data available prior to observing the period of
treatment interruption, such as viral outgrowth or PCR-based assays of the latent reservoir [12,
13], while the likelihood comes from the distribution of rebound times predicted by the model
(Fig 1). The product of the prior and the likelihood, when normalized by a constant factor,
gives the posterior distribution, reporting how probable each possible reservoir size is after
accounting for all information. By this method, the observed clinical follow-up serves to nar-
row down the (often very broad) reservoir size estimates obtained from other means.
Illustrative estimates using this approach are shown in Fig 2. Calculation details are pro-
vided in the Methods. The prior distribution (Fig 2a) is constructed by assuming that immedi-
ately prior to cART-interruption, the reservoir was sampled at a level of 100 times the pre-
reduction frequency of latently infected cells. For example, if there was 1 infectious unit per
million cells (IUPM) before the reservoir was reduced, then we suppose that 100 million cells
were sampled after reduction, none of which tested positive. To compute a prior from this neg-
ative assay result, we used a method based on Poisson sampling of the reservoir (summarized
in Methods and detailed in [14]). This prior represents a conservative “rebuttable presump-
tion” that reductions near 100-fold were the most likely outcome of therapy, and that a sub-
stantially greater reductions, while possible, should only be believed in the presence of
convincing evidence (e.g., very long period of treatment interruption without rebound). This
behavior is illustrated by the gradual slope downward on the right side of the graph in Fig 2a.
The prior also treats reduction substantially less than 100-fold as very unlikely, as otherwise
the post-treatment sample would almost certainly have returned a positive result; this behavior
is illustrated by the sharp plummeting to the left on the log y-axis. Fig 2b shows the posterior
estimates of the LR reduction efficacy, taking into account the observed time of rebound. A
point estimate can be determined by taking the median of the posterior distribution, and 95%
credible intervals can be constructed by taking the reduction efficacies between which 95% of
the distribution falls. The same method can be used to estimate reservoir sizes during the
course of trial, knowing only that rebound has not occurred prior to a certain time, but might
occur at some point in the future (Fig 2c).
Using this approach, 3 months without rebound implies an LR reduction of 500-fold (95%
range 110–7,900-fold), while rebound at 3 months would suggest a 250-fold reduction (95%
range 70–1,200-fold). For observations at 2 years, the corresponding estimates without
Designing HIV ART-Interruption Trials
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rebound are 3,500-fold [250–50,000] and with rebound are 1,300-fold [500–7,900]. Note that
observing rebound, as opposed to the absence of rebound, is predicted to lead to lower esti-
mates for LR-reduction (higher estimates for size) and narrows the confidence interval on
these estimates. However, all these results illustrate how the high variability between patient
outcomes makes it difficult to estimate precise estimates of reservoir size reduction.
Adaptive probability of cure
Intuition suggests that the longer a patient has been off treatment without rebound, the more
likely it is that they will never experience rebound, thereby achieving a cure. As above, we can
formalize this intuition using a Bayesian approach. Since the model gives a probability of cure
for each possible reservoir size (Fig 1b), we simply estimate a patient’s cure probability by com-
puting a weighted sum over that patient’s posterior distribution of LR sizes. Since this posterior
distribution changes over time (Fig 2c), the expected cure probability likewise changes over
Fig 2. Predicting and interpreting the outcomes of treatment interruption when the reservoir
reduction is unknown. A Bayesian approach is used to integrate information from reservoir assays with
model predictions to relate the time absence or occurrence of viral rebound following ART-interruption to the
remaining reservoir size. a) Prior distribution for the (unknown) reservoir reduction. We use as a prior the
post-test likelihood for each reservoir size after a negative viral outgrowth assay (see Methods). b) The
posterior probability for the LR reduction, given that rebound has occurred, using the posterior median (and
95% credible interval). c)The posterior probability for the LR reduction, as a function of the current time off
treatmentwithout rebound, using the posterior median (and 95% credible interval). d) The probability of
ultimate reservoir clearance (cure) as a function of the current time off treatmentwithout rebound. The initial
cure probability is near zero and again takes over a decade to reach high values. Note that the reservoir
reduction may either refer to the decrease in the number of latently infected cells in a given patient after
administering a latency-reducing therapy, or, the factor by which initial reservoir seeding was limited, relative
to a typical chronically infected patient.
doi:10.1371/journal.ppat.1005535.g002
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time (Fig 2d), increasing with the duration of the interruption. Assuming, as above, that a post-
reduction sample of 100 million cells test negative for latent infection, the cure probability
immediately following reduction is only around 1% and takes over 10 years to reach> 90%.
Required sample size to power studies of LR-reduction
If we consider a population of patients, then one major unknown is how many patients will be
required in a given clinical trial to reliably estimate the reservoir reduction efficacy (i.e. to
“power” the study). We can estimate this number using simulated patient data (details pro-
vided in the Methods). We assume that all patients respond identically to treatment, so that the
probability that any cell will be removed from the LR (and hence the expected value of the LR-
reduction) is the same for everyone. We define an adequately powered study size to be one for
which at least 95% of trials of this size would result in 95% credible intervals for the reservoir-
reduction that contain the true value and are less than 1 log wide. The calculation can be
repeated for any desired definition of adequate study power. Fig 3 shows how many patients
are required to achieve this goal. If the parameters governing viral dynamics are identical in all
patients (best estimates from [10]), then trials as small as 5–15 individuals can reliably estimate
reservoir reductions of up to 4 logs, while cohorts of 40 to 150 individuals are needed to resolve
reductions greater than 4 logs. For large reductions, outcomes are more variable and rebound
may even occur after the study follow-up period, which we assume here is 10 years.
Determining the optimal frequency of sampling during clinical trials
Our model results [10] as well as recent case studies [7, 25], have suggested that long-term
patient follow-up is necessary for LR-reducing interventions, due to the risk of viral rebound
even after long periods of remission. Frequent viral load testing for years after cART-interrup-
tion is expensive and time-consuming. Since rebound becomes less likely as a patient continues
off therapy without viremia, it may be reasonable to decrease the frequency of viral load testing
as time goes on. This model can be used to design an adaptive method for choosing the sam-
pling intervals.
Efficient sampling can be achieved by choosing intervals in which the probability of
rebound is constant, set to a pre-defined tolerance level. For example, we may decide that
between each scheduled viral load test, we can tolerate that 5% of the suppressed study partici-
pants experience viral rebound. The Bayesian approach above can be used to calculate the frac-
tion of suppressed patients expected to experience rebound, allowing us to choose sampling
intervals meeting the desired risk tolerance. Again supposing that 100 million cells test negative
for latent infection in an outgrowth assay, Fig 4a shows that, as expected, the recommended
sampling frequency is initially high, and then drops off after months-to-years off treatment
without rebound. Allowing for a 5% chance of failure between tests, the sampling frequency
peaks at 4 times weekly and falls off to less than once per week after about 100 days. After
about 1.5 years off treatment, the frequency drops to less than once per month. If we allow a
10% risk of failure between tests, sampling frequency peaks at only twice weekly and remains
lower than in the 5% case. Importantly, the recommended testing frequency depends on prior
information about LR reduction; if fewer than 100 million cells are sampled and tested for viral
outgrowth following LR reduction, then recommended frequencies would increase.
Note that because patients without any LR-reduction generally take a few weeks to rebound,
the recommended sampling frequency is low initially and only peaks about three weeks after
ART-cessation. However, other clinical concerns may favor beginning high-frequency testing
immediately after interruption. For example, if a patient was not fully compliant with cART
before interruption, viral replication may not have been fully suppressed, allowing viral
Designing HIV ART-Interruption Trials
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rebound to occur very quickly. The sampling intervals in Fig 4b accounts for this concern and
provides a simplified scheme for 5% rebound tolerance that may be more convenient for clini-
cal protocols.
This sampling scheme assumes that the goal is to keep the chance of rebound constant and
low between follow-up visits, not to stop rebound as soon as possible. If one wants to ensure
that rebound is caught very quickly and high level viremia is prevented, then sampling must
Fig 3. The required trial size to accurately and precisely estimate the LR-reduction. For each possible
known LR-reduction (x-axis), we determine the number of patients in a trial (y-axis) needed so that at least
95% of trials of this size would result in 95% credible intervals for the estimated reduction that contain the true
value and are less than 1 log wide. We sample hypothetical patients using our model, either with identical
best-estimated parameter values (dark blue line), or allow interpatient variation from a range of possible
values (cyan line); see distributions and data sources described in [10] and S1 Text). We assume that all
patients in the trial experience the same reservoir reduction (with only binomial variation in the actual number
of cells remaining), and that patients are followed for a maximum of 10 years.
doi:10.1371/journal.ppat.1005535.g003
Fig 4. The optimal frequency of viral load sampling during supervised treatment interruptions. a) We calculate sampling times such that the
probability of viral rebound between each test is equal and small—either 5% (dark blue line) or 10% (red line). These times are then transformed
into intervals and expressed as the number of recommended samples per month. For these results we use the same prior distribution for the
reservoir size as Fig 2a. The recommended frequency starts off low, before jumping to high values, because even without any reservoir-reduction,
rebound rarely occurs within the first two weeks in patients who have been on suppressive cART. More frequent initial monitoring may be
advisable if it is suspected that patients were not suppressed before interruption. b) A simplified sampling scheme that involves only regular
intervals and assures less than 5% chance of failure between measures.
doi:10.1371/journal.ppat.1005535.g004
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continue at a very high frequency indefinitely. Viral load can go from below 50 copies/ml to
104 in around 2 weeks in patients with intact immune responses (exponential growth rate
around 0.4/day), and perhaps in in as little as five days in those without HIV-specific immu-
nity, as seen in the example of the Boston patients [7] discussed below.
Potential for reservoir reseeding during treatment interruptions
One controversial aspect of treatment interruption trials is that if viral rebound occurs and is
undetected for a long time, the reservoir may be reseeded, thereby undoing any benefit of the
reservoir-reducing intervention. The extent of this reseeding is believed to depend on the total
number of cells newly infected during the time that rebound is undetected, which in turn
depends on the concentration of virus in the body (approximated by viral load in RNA copies
per ml of plasma) and the abundance of cells available to be infected (approximated by the con-
centration of CD4+ T cells in cells per μl of plasma). As detailed in S2 Text, models suggest that
the product of viral load and CD4+ count, integrated over time, should determine the number
of new latently infected cells generated. This expectation was confirmed during the period of
LR seeding that occurs in acute infection [26], and we use the empirical relationship observed
in that paper to estimate LR reseeding after rebound. As a worst-case scenario, we assume that
viral rebound begins prior to the most recent negative viral load test, such that viral load is just
below the limit of detection at this time, and that it continues to grow according to a simple
dynamic model until the infection is detected at the next sampling time and ART is re-initiated
immediately. Fig 5a demonstrates that if patients are sampled infrequently, the LR could
quickly return to a pre-treatment value ( 1 IUPM). More sensitive assays can reduce the
potential for reservoir reseeding if sampling occurs at least every two weeks. Most reservoir
reseeding occurs during peak viremia, and once viral load reaches a set-point, reservoir sizes
increase much more slowly over time.
Sensitivity analysis for uncertainty in viral dynamic parameters
In the analyses presented thus far, we have assumed that the parameters governing reservoir
dynamics and rebound—which are inputs to the model—are known and are identical between
patients. Point estimates for each parameter come from multiple data sources and their deriva-
tion is detailed in [10]. However, uncertainty in these parameters remains. Here we consider
how this uncertainty influences the methods we have described for interpreting rebound times.
Details of the parameter ranges we considered, the numerical methods, and the results are pro-
vided in Deriving priors.
Including parameter uncertainty has two important effects. Firstly, it leads to more uncer-
tainty to interpreting the reservoir size from time of rebound in individual patients. Delayed
rebound could be due to few remaining latent cells or particularly favorable parameters, so lon-
ger remission times are less informative about the reduction efficacy alone. However, even with
the broad parameter ranges considered, we find that these methods are still informative. For
example, for the situation outlined in Fig 2, the pre-interruption median [95% CI] interval for
the LR reduction based on laboratory assays alone was 2.16 [1.38, 3.41] logs. If the parameters
are known precisely, then after 6 months without rebound this is increased to 3.00 [2.16, 4.21],
while if the parameters are uncertain (with distributions given in S1.1 Table in Deriving priors),
then it is still increased but only to 2.63 [1.63, 4.03] (see S1.1 Fig in Deriving priors). To test
how much uncertainty could exist before rebound times become uninformative, we systemati-
cally increased the variance in one of the most important parameters governing rebound times
—the rate at which latently infected cells become reactivated. We found that this information
breakdown does not occur until the log-standard deviation increases by around four-fold (S1.2
Designing HIV ART-Interruption Trials
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Fig in Deriving priors). At this point, the observation of 6 months without rebound only
decreases our estimate for the remaining reservoir size by around 0.1 log. This level of variation
is unlikely to be biologically feasible, as it corresponds to around 107-fold difference in the acti-
vation rate between the central 95% of individuals, suggesting our methods are robust to realis-
tic levels of uncertainty.
Secondly, uncertainty in viral dynamics parameters means that the sample size required in a
clinical trial to narrow down the efficacy of a reservoir-reducing intervention is increased (Fig
3, cyan line). To model this, we assumed that individual patients in a population have unique
parameters which are randomly drawn from the ranges described (Deriving priors, [10]). In
this case, study sizes of at least 40 are expected to be needed to reliably estimate any reduction
efficacy. However, for nearly complete reservoir eradication, this interpatient variation actually
decreases the required trial size to power studies. This occurs because when patients vary in
reservoir reactivation dynamics, cure is predicted to be more common for small reservoir
reductions but less likely for large reductions, due to the presence of a portion of patients with
particularly favorable or unfavorable parameters. Since it is easier to estimate reduction efficacy
from the occurrence of rebound than from the absence of it, fewer cures mean lower required
trial sizes.
Overall, this sensitivity analysis demonstrates that even in the face of uncertainty about the
viral dynamics parameters, observing rebound times always improves our estimates of the res-
ervoir size following latency-reversing interventions beyond the estimates obtained from pre-
interruption assays alone.
Fig 5. Impact of assay sensitivity and time between viral load samples on potential reservoir reseeding during rebound. a) We estimate how
much re-seeding of the LR could occur between when viral rebound occurs and when it is detected, using a method for estimating LR sizes previously
validated during acute infection [26]. We assume the LR size is very small (approx. zero) before interruption, though if it is larger these values represent
the increase in size. LR size is measured as the frequency of infectious provirus among resting CD4+ T cells (IUPM = infectious units per million). We
consider assay detection limits of 2 (dark blue), 20 (cyan), and 200 (red) copies/ml, and assume a worst-case scenario where viral load is just below
this value at the last undetected sampling point. Smaller figures on the right show the b) viral load and c) CD4 count trajectories over time that
generated the IUPMmeasurements in the larger figure. Time is measured relative to the time viral load reached the detection limit, and we assume
detection does not occur until this value is surpassed.
doi:10.1371/journal.ppat.1005535.g005
Designing HIV ART-Interruption Trials
PLOS Pathogens | DOI:10.1371/journal.ppat.1005535 April 27, 2016 10 / 26
Applications to allogeneic hematopoietic stem cell transplantation in the
“Boston patients”
We consider two such HIV+ individuals who underwent cytotoxic chemotherapy and alloge-
neic hematopoietic stem cell transplantation to treat hematological malignancies. They have
since become widely referred to as the “Boston patients.” Detailed clinical and virologic data
for these individuals is reported elsewhere [6, 7], but summarized in Table 1, along with the
results of our modeling work described in subsequent sections. Before transplant both patients
had been on long-term cART, and had reservoir sizes (measured by presence of HIV DNA in
PBMC) consistent with chronic infection. During transplant engraftment, transient viral load
“blips” were detected although cART was continued. Three to four years post-transplant,
engraftment appeared to be complete, as microchimerism assays detected residual host cells at
levels of less than 0.001% in peripheral blood. Assays for plasma or latent virus returned no
positive results. Due to lack of detectable HIV, both patients interrupted ART in a supervised
manner. No free or integrated virus was detected until 3 and 8 months post-interruption, at
which point plasma virus rapidly rebounded. Because these transplants occurred in the context
of wildtype CCR5 (unlike the “Berlin patient” [5, 27]), the mechanism for delayed rebound is
believed to be a reduction in the latent reservoir, suggesting it is well-suited to analysis by the
modeling framework described in the previous section. We will examine how this analysis
could have been used in real-time to interpret the outcomes of these patients, and how it can be
used retrospectively. We will present and analyze the available clinical data on these patients in
chronological order of how it was released to the public during the study. Note that for this
analysis, we assume that the parameters governing reservoir and viral dynamics at the time of
ART interruption are the same in these patients as in other treated HIV+ patients who did not
receive transplants, including the rate of turnover and reactivation of latent cells, and the viral
replication rate of reactivated lineages.
Predicting and interpreting outcomes for the Boston patients in real time
We examine the clinical and virologic data available for the “Boston patients” in the order
released to the public, considering how additional modeling analysis could augment these data.
At the time of treatment interruption, for each patient, a large number of CD4+ T cells were
isolated and used in a viral outgrowth assay to measure the reservoir size. In each case the
results were completely negative, and so using the approach described in the Methods and
[14], we can create a post-test distribution for the likely size of reservoir. This distribution,
described in terms of log-reduction from a baseline value of 1 IUPM, is created analogously
to the distribution shown in Fig 2e. The median of this distribution is near 0.004 IUPM for
both patients. Using this distribution as a prior for the unknown reservoir reduction, we can
then estimate the probability each patient will be cured (i.e. not experience rebound), the day
by which there is 50% chance that rebound will have occurred, and the recommended sampling
frequency (reported in Table 1). Because it is still reasonably likely that the reservoir is quite
large, the model predicts that sampling should occur frequently (every few days if the tolerance
is 5% failure between samples), and that rebound is very likely to occur within the first few
months.
The predictions can be updated throughout observation of the interruption trial. The first
report of these patients was made public in June 2013 [28], describing that they had experi-
enced antiretroviral-free remission for 8 and 15 weeks. Adding this information to the model
results in more optimistic predictions (Table 1). The updated posterior median estimate for
reservoir size is now reduced to 0.0028 and 0.0016 IUPM, for Patients A and B. This justifies
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only a small improvement in the expectation of cure, rising from 2% for each patient to 3% and
6%, respectively.
In December 2013 [29], it was reported that both patients had rebounded, after a total of 84
and 225 days. The posterior estimates for reservoir reduction based on this final piece of infor-
mation are not much larger than the prior estimates obtained from the negative viral out-
growth assay results (median of 2.35 logs reduction versus 2.33 for Patient A, 2.75 versus
2.37 for Patient B, see Table 1), and the 95% credible intervals for the prior and the posterior
overlap considerably. In other words, the final outcomes were not terribly surprising from the
standpoint of the initial negative assay results, and had the same outgrowth assays been per-
formed a second time prior to ART interruption (PBMC sample permitting), they may very
well have shown a positive result.
Table 1. Reservoir quantification and rebound dynamics for the two “Boston patients”.
Time Quantity Patient A Patient B Method
Pre-transplant LR size (HIV DNA/106 PBMC) 144 69 Measured*
During transplant Detectable viral blips (fraction of sampling points >
2 c/ml)
2/9 1/7 Measured
Pre-ART Interruption Time on ART
Host chimerism
# CD4+ T cells used in VOA
Positive VOA results
Posterior median LR size from VOA [95% CI] (IUPM)‡
4.5 years
<0.001%
1.50 × 108
0
0.0046 [0.00034,
0.020]
2.5 years
<0.001%
1.60 × 108
0
0.0043 [0.00032,
0.019]
Measured
Posterior median LR reduction from VOA [95% CI] (logs)
Posterior median LR size from VOA [95% CI] (# of cells)‡
# Remaining infected host cells
# Newly infected donor cells entering latency
2.33 [1.70, 3.47]
4600 [340, 20000]
8 [1, 420]
11000 [0, 110000]
2.37 [1.72, 3.49]
4300 [320, 19000]
7 [1, 390]
5700 [0, 57000]
Estimated***
Day 1 ART-
Interruption
Recommended sampling frequency†
Probability of cure
50% rebound by
every 3 days
1.9%
63 days
every 3 days
2.1%
66 days
Predicted from model**
June 2013 reportk Time without rebound 56 days 105 days Measured
Recommended sampling frequency†
Probability of cure
50% rebound by
Posterior median LR reduction [95% CI] (logs)
every 4 days
3.4%
120 days
2.55 [1.95, 3.75]
every 6 days
6.0%
225 days
2.80 [2.20, 4.00]
Predicted from model
Dec 2013 report¶ Time of rebound 84 days 225 days Measured
Posterior median LR reduction [95% CI] (logs)
Posterior median LR size [95% CI] (# of cells)
2.35 [1.90, 3.00]
4500 [1000, 12600]
2.75 [2.30, 3.45]
1800 [350, 5000]
Predicted from model
During rebound Viral growth (rate/day; R0)
Genetically distinct cells from which rebound started
Potential reservoir reseeding (IUPM)
 1.24
 1
 1
> 0.82
 1
 1
Estimated
* “Measured” quantities are those determined experimentally and reported in the aforementioned papers.
**Quantities “Predicted by the model” involve the stochastic model of reservoir dynamics and rebound [10].
***“Estimated” values are obtained using other viral dynamics considerations, as described in the text.
kThe June 2013 report was the first public description of the patients after treatment interruption, and released the current times for which each had remained
off ART.
¶ The Dec 2013 report first presented the finding that both patients had experienced viral rebound.
VOA = viral outgrowth assay.
†The recommended sampling frequency is obtained by allowing for a 5% failure rate between samples.
‡ The reservoir size is translated between IUPM, number of cells, and log-reduction by assuming the baseline size is 1 IUPM or 106 latently infected cells
(and therefore that there are 1012 total CD4+ T cells)
doi:10.1371/journal.ppat.1005535.t001
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Estimating the size and source of the reservoir post-transplant
The case of the Boston patients highlights the fact that even after finding negative results in
viral outgrowth assays of latency, a wide range of reservoir sizes are consistent with the data.
Once rebound is observed, the time of rebound can help to narrow this range when interpreted
in the context of a mathematical model of rebound dynamics. In the context of HSCT, observ-
ing rebound prompts the question of where the rebounding viral lineage originated. Two
sources are possible: host cells that survived chemotherapy and graft-vs-host disease, and
donor cells that later became infected and entered latency. A schematic of potential changes in
reservoir size over the course of transplant, depicting both possible sources, is shown in Fig 6.
Here we show how other experimental data can help us understand the source of rebound
viremia following transplant and provide independent estimates for the size of the remaining
reservoir. Note that in the case of the Boston patients, sequence analysis of pre- and post-trans-
plant virus showed high relatedness, ruling out superinfection as a likely cause of viral rebound
[6, 7].
Remaining reservoir in host cells. Pre-transplant chemotherapy and post-transplant
graft-vs-host-disease [6, 30, 31] may not be 100% effective at removing all host cells, and some
host cells that comprised the LR may remain at a low frequency. The efficiency of engraftment
in these patients was measured by allele-specific PCR of PBMC to identify host vs donor cells
(“micro-chimerism”) [6], which found host cells to remain at a frequency less than 10−5
(0.001%) in the peripheral blood. This result suggests that the reservoir in host cells was
reduced by at least 5 logs. To translate this value into an actual reservoir size (in terms of
IUPM or number of infected cells), we need to know the pre-transplant LR size. The major dif-
ficulty in making this estimate is that reservoir sizes before transplant were only measured as
the fraction of PBMC that contain HIV proviral DNA. Only a small portion of this integrated
provirus is believed to be intact and able to produce virions [32]. Accordingly, the frequency of
infectious cells as measured by viral outgrowth assays is much smaller than PBMC HIV DNA
levels [12]. Moreover, there is only a weak correlation between the two measurements, and it is
unclear which of these measurements is the best proxy for the true “functional” size of the res-
ervoir from which viral rebound can occur. However, we can use them as upper and lower
bounds on the reservoir size. As detailed in Deriving priors, we use previously determined
ratios between these different assay measurements to estimate reservoir frequencies for Patient
A and B of 7.5 (0.75, 420) ×10−6 and 6.9 (0.69, 390) ×10−6 respectively, which, assuming a total
of 1012 resting CD4+ T cells, corresponds to 8 [1, 420] and 7 [1, 390] infected cells remaining.
New infection of donor cells. Both patients received transplants from HIV-negative
donors, and so any possible contribution to the latent reservoir from donor cells must have
been due to new latent infections occurring during the transplant procedure. Both patients also
remained on cART during the entire engraftment procedure, which was thought to prevent
any new infection. Several independent lines of evidence suggest that viral replication halts
during optimal adherence to cART: treatment reduces viral replication several orders of magni-
tude in vitro [33, 34], evolution of the viral population appears to stop in vivo [35, 36], and
intensified treatment does not further reduce viral load [37, 38]. Yet it is possible that short
lapses in adherence [39], or the presence of cellular compartments with poor drug penetration
[40], may compromise the effectiveness of cART, allowing low levels of new infection. Note
that if this replication was ongoing until the time cART was interrupted, then viral rebound
would be expected to occur immediately. The long delay until rebound implies that any ongo-
ing replication was transient, so that upon treatment cessation rebound could not occur until a
latent cell successfully reactivated. We estimated ranges for the number of latently infected
donor cells formed by the time of cART-interruption using a method that was agnostic to the
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particular cause of ongoing replication. Following most viral dynamics models, we assumed
that these cells are produced at a rate determined by the product of the viral load, the density of
target CD4 cells, the infectivity, and the probability of infection resulting in latency. We used
longitudinally observed levels of residual viremia and CD4 counts observed for each patient,
and took bounds on the rates of infection and entry into latency during cART obtained from
previous studies [26, 41]. As detailed in Deriving priors, the estimated ranges for the contribu-
tion to the latent reservoir from donor cells is 11,000 [0, 110,000] for Patient A and 5,700 [0,
57,000] for Patient B.
Fig 6. Schematic of potential cell and viral dynamics during hematopoietic stem cell transplant with
suppressive cART. Solid circles: recipient cells. Open circles: donor cells. Red: HIV+ cells. The recipient
patient starts out with high levels of CD4+ T cells, a small fraction of which are latently infected with HIV.
Following conditioning chemotherapy, recipient cell levels drop. When donor cells are transplanted, recipient
cells continue to decline as donor cells increase in number. If any ongoing viral replication occurs during
engraftment, donor cells may become HIV-infected. Without new infections, the latent reservoir size should
decrease proportionally to the frequency of recipient cells, but new infection of donor cells may quell this
decrease. Viral blips may occur during transplant, perhaps due to imperfect cART adherence or immune-
modulated viral re-activation. If cART is interrupted, then any remaining latently-infected cells—either from
the recipient or donor—may reactivate and lead to viral rebound.
doi:10.1371/journal.ppat.1005535.g006
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Despite the considerable uncertainty in these values and the estimated reservoir reductions,
they do constrain the possible causes of viral rebound. Specifically, in Patient A, it is difficult to
explain the observed rebound time without positing that some donor cells were newly infected.
The 95% credible interval for the posterior estimate of the LR size estimated from the observed
time of rebound suggests there were many more cells in the reservoir than were likely to remain
from the recipients pre-transplant infection. However, if the efficiency of donor engraftment in
tissues was lower than that in the peripheral blood, then enough latently infected host cells
could have remained to explain the rebound time. In Patient B, on the other hand, the presence
of new infection is not necessary to explain the observed rebound, as the upper bound on the
number of residual host cells is consistent with the lower bound for the reservoir size estimated
from the time of rebound.
Analyzing rebound dynamics in the Boston patients
The dynamics of viral load following rebound can be used to estimate the rate of viral replica-
tion, to compare these two patients to other treatment interruption cohorts, and to examine
potential reservoir re-seeding. For Patient A, there are two consecutive viral load values above
the detection limit, before peak viremia and set-point are reached (900 c/ml at Day 84 and 130
000 c/ml at Day 88). From these, we estimate that the rate of exponential increase in viral load
is r 1.24/day. This is higher than any of the values observed in non-transplant interruption
studies (average 0.4/day, range 0.1–0.9) [10, 18, 42]. For Patient B, only one viral load value is
available before cART was restarted, but from this (Day 225, 1 900 000 c/ml) and the last unde-
tectable time point (Day 211,<20 c/ml), we can determine that r is at least 0.82/day. Overall
these values suggest that viral replication is accelerated, or death of infected cells is inhibited, in
HSCT patients due to loss of HIV-specific immune responses that may occur during the long
period in which viral antigen is largely absent. In fact, these rates of viral increase are compara-
ble to those observed during acute infection, prior to establishment of HIV-specific immune
responses [43].
One of the predictions of the model of rebound dynamics is that if rebound occurs after a
long delay, it is likely to be caused by a single cell that has reactivated from the latent reservoir.
Significant delays in the rebound time only occur when the waiting time between latent cells
reactivating is long, and since we assume that cells reactivate independently, the chance that
more than one cell would start producing virus at nearly the same time is very low [10]. If this
prediction is correct, then rebounding viremia should be highly genetically similar within the
exponential growth phase, comparable to the viral population at the start of a single-founder
HIV infection [44]. Phylogenetic analysis of rebounding viral lineages in both patients did
indeed find that the sequences formed a distinct genetic cluster apart from the more diverse
pre-transplant HIV DNA [7], thus supporting the mechanism of rebound suggested by the
model. An alternate explanation for this lack of diversity in rebound viremia is that the latent
reservoir is maintained by cellular proliferation, giving rise of clones of identical provirus [45–
48]. In that case, multiple simultaneously reactivating cells may be indistinguishable from one
another. A recent study has found, however, that most of these clones contain defective provi-
rus [49], decreasing the plausibility of this alternate explanation. Moreover, another recent
paper examined the genetic structure of viral populations when rebound occurs rapidly in
patients without reservoir-reducing interventions [50], and found diverse lineages in most
patients. This finding is consistent with multiple cells exiting the reservoir each day when it is
at a baseline size, in contrast to the case of HSCT patients.
At the time of rebound, both patients had viral load measurements taken every 2 weeks with
a detection limit of 20 RNA copies/ml. According to the model behind Fig 5, the worst-case
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scenario for reservoir reseeding by the time virus is detected, assuming rebound begins imme-
diately after the last negative test result, is about 0.5 IUPM for this measurement schedule and
the rapid rebound rate seen in these individuals. For Patient A, rebound was detected at only
900 c/ml, suggesting (based on the observed rate of exponential growth) that virus only became
detectable around 4 days before and that the reservoir size could have been limited to around
0.05 IUPM if ART had been re-initiated immediately. In reality treatment was not initiated
until several days later, when viral load reached around 1.2 × 105 c/ml, and suboptimal adher-
ence led to even higher values before suppression was eventually achieved. In contrast, for
Patient B the first positive viral load value was already likely near the pretreatment peak, at
1.9 × 106 c/ml, so even though treatment was initiated promptly leading to rapid viral decline,
near-complete reservoir reseeding may have been inevitable.
Discussion
One of the proposed strategies to cure HIV infection is to reduce or eliminate populations of
latent virus that persist despite long-term antiretroviral therapy. The goal of these strategies is
to allow individuals to stop cART without experiencing rebound of viremia. However, case
studies such as the “Mississippi baby” [8] and the “Boston patients” [7] highlight the difficulties
in conducting clinical trials of reservoir-reducing interventions. Most worryingly, these cases
demonstrate that latent virus levels can be undetectable with current technology and still cause
rebound after long delays. As a result, long-term follow-up during cART interruption is needed
to verify viral eradication. In this paper we have used a combination of mathematical and sta-
tistical modeling techniques to guide the design and interpretation of clinical trials for novel
curative interventions. This framework includes a method to estimate the size of the remaining
latent reservoir and the probability that the infection is cured, based on the delay in viral
rebound following cART-interruption. The same framework also can be used to determine
adequate trial cohort sizes to make these estimates; to optimize the schedule of viral load testing
during supervised interruption; and to estimate the extent of reservoir reseeding if rebound
goes undetected, which is a risk for any interruption trial.
One of the most useful features of our approach is that it offers a formal way to combine
information from pre-interruption assays of the latent reservoir size, even if they are all nega-
tive, with observations during treatment interruption. Our analyses predict that even if no
infection is detected among approximately 100 million cells assayed, 4 years of follow-up are
needed before there is a 50% chance of cure, and over 10 years to be 90% sure. The higher cell
samples that could be obtained with leukophoresis ( 1 billion) only decrease these follow-
up times by around a year. An implicit assumption of this approach is that there is a dynamic
equilibrium between latently infected cells in the tissues and those circulating in the periph-
eral blood. If a reduction observed in the blood does not correspond to the reduction in the
tissues, these estimates will be biased. Consistent patient monitoring during treatment inter-
ruption is necessary, and how the frequency of sampling should be scaled-back as time pro-
gresses and cure becomes more likely is not intuitive. We used the model predictions to
design a sampling schedule so that the chance of patient rebound between samples remained
at a constant low level. It suggests times after which sampling frequency could be reduced to
weekly (5 months), monthly (1.5 years), quarterly (5 years), and annually (10 years). How-
ever, even when the risk of rebound between samples is low, if it does occur, the risk of reach-
ing high-level viremia and completely reseeding the reservoir before the infection is detected
may be high.
Even when the post-intervention reservoir size is informed by negative assay results and a
precise measurement of viral rebound time, there is considerable uncertainty in its size. This
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uncertainty in residual HIV reservoir size follows from the stochastic nature of viral rebound
from small latent reservoirs. This stochastic process produces large variability in viral rebound
times, even for patients starting with identical reservoir sizes [10]. As a result, large trial sizes—
between 40 and 150 individuals—will probably be necessary to reliably estimate the reservoir-
reducing potential of a new therapy and to compare this across interventions.
Many of our estimates (Figs 2–4, Table 1: “Predicted from model”) rely on a mechanistic
model of rebound dynamics that was developed and detailed in a previous manuscript [10].
The model we developed treats the latent reservoir as a homogeneous population of cells, in
which activation and subsequent release of infectious virus particles is assumed to be a probabi-
listic event occurring independently for each cell. While sufficient data does not yet exist to val-
idate this model formally, independent confirmation of some of its predictions suggest that the
model is informative and relevant. The model independently predicted that rebound may
occur after months to years after cART cessation as observed in the Mississippi and Boston
cases [7, 8]. Genetic analysis of rebounding viral lineages suggests that rebound may be caused
by multiple lineages when reservoir sizes are high and rebound occurs rapidly [50], but only
single lineages when reservoir sizes are undetectable and rebound is delayed, such as in the Bos-
ton patients [7]. These findings are consistent with the model, in which delays in rebound were
due to a decrease in the daily reactivation rate of latently infected cells.
Quantitative predictions of the model depend on parameters governing rebound dynamics.
As described in the first section of Results, four parameters play an important role: the half-life
of the pool of latently infected cells, the activation rate of latently infected cells, the viral growth
rate after activation, and the probability that a single activated cell establishes a growing infec-
tion. Biological details of viral and cellular dynamics, including the proliferative mechanisms
maintaining the latent reservoir, the length of the “eclipse phase” during which a cell does not
produce virus particles, and the number of virus particles produced by a single infected cell,
were seen to have only minor effects on rebound [10]. Accordingly, in the current paper, we
have not considered these additional details and have confined sensitivity analysis to the four
main parameters alone (Deriving priors). There is broad consensus regarding measurement of
the half-life of the latent reservoir for patients on ART and the viral growth rate following
rebound: Longitudinal studies of latent reservoir size show a half-life of about 44 months for
the typical patient [15, 16], and viral load dynamics show an exponential growth rate of about
0.4 per day for the typical rebound event [17, 18]. Direct estimates of the latent cell activation
rate and the establishment probability are difficult to make, and there is ongoing debate regard-
ing methods to measure them [51, 52]. The problem is essentially one of observing extremely
small numbers of cells in vivo: in an ART patient with a fully-suppressed viral infection, there
may be fewer than 100 actively infected cells present at any one point in time [10], and it is not
feasible to count, much less track the fate of, each one of these cells. For now, the field must
pursue indirect measurements [10, 24], informed by viral dynamics [17, 18], population genet-
ics [21–23], in vitro virology [19, 20, 53], and the timing of viral rebound [51, 52]. Improve-
ments in these estimates will be invaluable to the field, since indirect, model-based methods for
interpreting treatment interruption trials will be necessary until ultrasensitive assays for the
latent reservoir are created.
Our dynamic model of viral rebound assumes that the administration of cART halts contin-
uous cycles of ongoing replication. As a result, at the time of treatment interruption, only
latently infected cells or cells that recently reactivated from latency remain. The existence of
ongoing viral replication during cART is a hotly debated topic, but observations that viral evo-
lution is limited during treatment [35, 36] and that treatment intensification fails to reduce
viral load [37, 38] suggest it is minimal. Reservoir stability can be explained without ongoing
replication by known homeostatic mechanisms that maintain immunologic memory [54] and
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a proliferative process related to sites of viral integration [48, 55]. When we attempted to obtain
a worst-case scenario estimate for the number of donor cells that could have become infected
and entered latency during HSCT in the Boston patients (despite administration of cART)
(Table 1), we did consider the possibility that some limited replication could have occurred.
We derived upper limits for the ongoing latent infection rate from studies that tracked the
movement of specific genetic sequences between the plasma and reservoir during cART [41],
and also by adjusting the latency formation rate during acute infection [26] by the estimated
efficacy of cART [33, 34]. In contrast to the mainstream focus on latency as the main barrier to
an HIV cure, others researchers maintain that continuous cycles of viral replication carry-on
throughout cART treatment. For example, a new study by Lorenzo-Redondo and colleagues
[56] finds increasing phylogenetic divergence over time during cART, suggesting this as evi-
dence for ongoing replication and evolution. If there are indeed patients in whom replication
persists, different factors than considered in our model could influence rebound time. We
would expect rebound to occur more quickly, since it is limited only by viral growth and poten-
tially migration from a drug sanctuary. At this stage it remains unclear whether the genetic pat-
terns seen by Lorenzo-Redondo et al necessarily imply ongoing replication, or whether they
could also be explained by decay of labile infected cell populations over the first few months of
treatment [57] or by cell-proliferation driven changes in the frequency of particular integrated
proviruses over time [46, 48]. In this continued presence of uncertainty about ongoing replica-
tion, we have focused on the role of viral latency.
The statistical framework presented here could be adapted to any mathematical model
which similarly forecasts rebound. In particular, it can be applied to the model recently pro-
posed by Pinkevych et al. [51], who argued that the product of two of the parameters described
above—the activation rate of latent cells and the probability that a single activated cell manages
to establish a growing infection—is much lower than we have suggested (0.17 cells per day, ver-
sus 4 cells per day). This lower estimate implies that several months’ delay in rebound could be
achieved with less than one log-reduction. For reasons fully detailed in a separate publication
[52], we believe that the Pinkevych et al. model underestimates this product by not appropri-
ately accounting for interpatient variation in latent reservoir size and viral growth rates when
interpreting data from treatment interruption studies. Our analysis therefore employs our orig-
inal model and parameter estimates.
An additional limitation of the model is that it assumes that the intervention reducing reser-
voir size is homogeneous and does not change the parameters governing reservoir or virus
dynamics. While the latter assumption seems reasonable for treatment with some latency-
reversing drugs, HSCT drastically perturbs the immune system, which may in turn alter the
rate at which latently infected cells proliferate, die, or reactivate. It may also alter the growth
patterns of viral lineages that stem from reactivated cells. For our analysis of reservoir size and
rebound times, we assumed no change in these rates. The one parameter we could easily mea-
sure—the viral growth rate during rebound—did appear to be larger than the value in non-
transplanted individuals, perhaps due to a loss of HIV-specific immunity. This parameter,
however, has a small effect on the time to rebound relative to others [10]. If there were evidence
to suggest the reactivation rate of latent cells was higher in these patients due to GVHD or
other effects, then the observed rebound times would be consistent with lower reservoir sizes
than estimated in our analyses. Another consequence of the simple way in which the model
treats the immune system is that it cannot predict rare phenomena such as post-treatment con-
trol [58, 59]. This shortcoming, however, may have little effect on prediction of rebound in the
large majority of patients. We have assumed that the latent reservoir is a homogeneous popula-
tion of cells, because at this stage little information is available about phenotypically different
compartments and how these may vary in response to LRAs. However, one alternate scenario
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is easy to study with our model. If the reservoir consists of two compartments—one which is
completely reactivated and cleared by the LRA, and one which is not affected at all –then the
results our identical to the ones presented here, as long as the reduction efficacy is interpreted
as the fraction of latent cells that reside in the unaffected compartment.
We used a separate model, not relying on the above assumptions, to estimate the extent of
reservoir reseeding during rebound (Fig 5) and the number of donor cells infected by ongoing
replication during engraftment (Table 1). This model predicts the number of latently infected
cells using longitudinal viral load and CD4 count data, based on regression coefficients esti-
mated from a cohort observed during acute infection [26]. Although this model is mechanisti-
cally grounded in viral dynamics theory [60] and empirically grounded by cohort data, its
predictive ability is imperfect. The best-fit model from Archin et al [26] was only able to esti-
mate reservoir sizes to within approximately 1-log of the observed values, and we have used
this finding to put error bounds on our estimates. Additionally, the log-linear regression
Archin et al used to estimate latent infection rates deviates from the linear relationship pre-
dicted by viral dynamics theory, suggesting that the theory behind these predictions is incom-
plete and that extrapolating beyond the range of observed data, as we’ve done here, may be
problematic.
Progress in HIV cure research is challenged by major uncertainties—uncertainty over the
size and persistence of the infected cell population that must be eliminated to achieve a cure,
uncertainty over the immediate effect of potential curative interventions, and uncertainty over
the long-term benefits and risks of such interventions. A mathematical framework that incor-
porates mechanistic modeling and Bayesian statistics will play a key role in managing these
uncertainties, enabling the design and interpretation of clinical trials.
Methods
Ethics statement
This manuscript involves the analysis of previously published data from human studies, and
details of the ethical approval can be found in the original publications [6, 7].
Bayesian approach to interpreting trial outcomes
If q is the reduction efficacy, defined as the fraction of latent cells remaining after reservoir-
reducing therapy, then we define S(t j q) be the fraction of patients who have not yet rebounded
at a time t after treatment is stopped. Since we do not know the true function S(t j q), we rely
on the predictions calculated from the model. For any fixed q value, the function S(t j q)
describes “survival curves” that can be calculated from the model (Fig 1C). The details of the
model dynamics and parameter estimation are described in detail in a previous manuscript
[10].
We first approach the question of how to estimate the amount by which the reservoir has
been reduced, when we cannot measure reservoir size directly from assays but have observed
delayed viral rebound. We consider a patient who has still not experienced viral rebound after
τ days after ART-interruption (rebound time tr is greater than τ). We define P(q) to be the
probability distribution for our existing knowledge about the likelihood of a given q value
being the true value (the prior). This function can be estimated using data from experimental
assays, as detailed in the next section. The function S(τ j q) forms the likelihood of the Bayesian
approach, which gives the probability of the data (τ) given a particular model (the unknown
reduction-efficacy parameter q). Then, the posterior probability distribution for the reduction
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efficacy q becomes:
Ppostðq j tr > tÞ ¼
Sðt j qÞPðqÞR
q Sðt j qÞPðqÞdq
ð1Þ
Alternatively, if a patient rebounded at a time τ, then the formula is slightly modified. The like-
lihood function for the time of rebound is given by the slope of the survival curves, @S(τ j q)/@t,
so the posterior probability for the reduction efficacy q becomes
Ppostðq j tr ¼ tÞ ¼
@
@t
Sðt j qÞjtPðqÞR
q
@
@t
Sðt j qÞjtPðqÞ
 
dq
ð2Þ
We next turn to determining the probability that a patient is cured (i.e. will never experience
viral rebound, even if they were to live forever), as a function of the current time they have
been off cART without rebounding. Eq (1) gives the posterior probability distribution for the
reduction efficacy q when a patient has survived without rebound for a time τ, for a given prior
distribution. We combine this with the fact that the probability of cure is given by the limiting
value of the survival curve as time increases to infinity, pcure(q) = S(1 j q), and that the condi-
tional probability of cure, given only those individuals who have not yet rebounded at time τ, is
pcure(q j tr> τ) = S(1 j q)/S(τ j q). Then, we can derive the probability of a cure, given the
absence of rebound until time τ, as
pcureðtr > tÞ ¼
Z
q
pcureðq j tr > tÞPpostðq j tr > tÞdq 
Fð1Þ
FðtÞ ð3Þ
where
FðtÞ 
Z
q
Sðt j qÞPðqÞdq ð4Þ
We can also estimate how many patients would be needed in a trial to narrow down the esti-
mated reservoir-reduction to something close to its actual value. We say that this is the trial
size required to adequately “power” the study, where we imagine that the main goal of the
study is to determine how much some novel intervention reduces the reservoir, and that this
can only be done by observing rebound times.
If there are n patients in a trial and a set of rebound times {τi} = {τ1, τ2. . .τn} are observed,
then the posterior distribution for the reduction efficacy q is given by:
Ppostðq j ftigÞ ¼
Y
i
@
@t
Sðt j qÞjti
R
q
Y
i
@
@t
Sðt j qÞjti
 !
dq
ð5Þ
Here we assume a uniform prior, as a worst case scenario where no other information on
reservoir size is available. If q is high enough so that after some time τmax,m patients still have
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not rebounded, then the estimated reduction efficacy becomes
Ppostðq; ftigÞ ¼
Sðtmax j qÞm 
Ynm
i¼1
@
@t
Sðt j qÞjti
R
q
Sðtmax j qÞm 
Ynm
i¼1
@
@t
Sðt j qÞjti
 !
dq
ð6Þ
The required number of patients n can be calculated for particular requirements on the pos-
terior estimate, by repeatedly simulating patient data and using it to construct Ppost. For exam-
ple, we defined a study as adequately powered if 95% of trials of this size would result in 95%
(centered) credible intervals for q that that contain the true value and are less than 1 log wide.
We determined n by doing a binary search though trial sizes from the list {5, 10, 15, 20, 25, 20,
40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000}. Here we
assume τmax = 10 years.
We additionally use these methods to estimate the optimal frequency of sampling subjects
in a cART-interruption trial. One method to optimally choose sampling time points is to deter-
mine intervals between which the chance of a participant experiencing viral rebound is equal.
If the reduction efficacy q is known, then the probability that someone who has survived
until timepoint ti rebounds before time ti+1 is
Prebðti; tiþ1 j qÞ ¼ 1
Sðtiþ1 j qÞ
Sðti j qÞ
ð7Þ
However, in the general case that q is unknown, we must again weight this probability with
the posterior likelihood of q, given that the patient has already survived without rebound until
time ti
Prebðti; tiþ1Þ ¼
Z
q
Prebðti; tiþ1 j qÞPpostðq j tr > tiÞdq ¼ 1
Fðtiþ1Þ
FðtiÞ
ð8Þ
Where F(t) is defined as in Eq (4). We set Preb(ti, ti+1) to the pre-defined “tolerance” δ—the frac-
tion of suppressed trial participants expected to rebound between each sampling timepoint. Using
t0 = 0 and F(t0) = 1, we can iteratively solve for tn using the implicit equation F(tn) = (1 − δ)
n.
We do not have analytic functions for the model output S(t j q), which means we cannot ana-
lytically calculate any of the integrals described above. Instead we use the simulated model out-
put to numerically construct S(t j q), using 10,000 patients for each q value and q values between
10−6 and 1 in increments of 0.05 logs. We then calculated the integrals as Reimann sums.
Deriving priors
The Bayesian approach to estimate the post-treatment reservoir size (q) as a function of
rebound time can incorporate any prior knowledge we may have about the likely reservoir size
(P(q)). This prior distribution can be constructed based on the results of virologic assays that
were used to measure the size of the reservoir before cART was interrupted.
Briefly, to construct P(q), we imagine an assay was performed that measured the frequency
of latently infected cells in a sample (e.g. by viral outgrowth or PCR). We assume that cells
used in the assay were randomly sampled from a much larger pool in a patient’s body. We can
then construct the likelihood distribution for the true frequency of latently infected cells, based
on the actual number of infected cells observed in the sample. We define the true frequency of
latently infected cells to be θq, where θ is the frequency before reservoir-reduction, and q is
the fractional reduction. If C cells are sampled and zero infected cells are observed, then the
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likelihood for q goes as P(q)/ e−θCq. (This is based on the Poisson approximation to the bino-
mial process when the number of samples is very high and the probability of success is very
low). This distribution shows that taking only negative assay results into account, any q value is
possible, but q = 0 (no remaining reservoir) is mostly likely and higher q values (larger reservoir
sizes) are less likely, although as q becomes very small, the distribution flattens out.
More details of this calculation can be found in separate manuscript [14]. Simple browser-
based software for calculating the full likelihood distribution for viral outgrowth assays, even
when positive results are detected, is available at http://silicianolab.johnshopkins.edu.
Using C = 108 and θ = 10−6 (i.e. the reservoir was sampled at a level of 100 times the pre-
reduction frequency of latency), then if no infected cells are detected, the resulting prior distri-
bution is shown in Fig 2a. Note that on a log-scale, larger reductions (e.g. between 5 and 6 logs)
appear less likely, which is simply because the density of numbers between these values is less.
The actual individual reservoir size value with the highest likelihood is still q = 0 (Q!1).
Other priors may also be possible, depending on the nature of the assay. The most uninfor-
mative prior would be to assume that we have no information on reservoir size before cART
interruption, and so every reservoir size is equally likely. We think this is unrealistic, since an
interruption trial would likely not be conducted unless the reservoir was undetectable or at
least very low by standard assays.
Note that it is common practice in clinical studies to interpret the results of the types of
assay described above as a hard cut-off for the reservoir size. It is often said that if no infected
cells are detected, then the frequency is less than the inverse of the sample size, i.e. θq< 1/C, or
q< 1/(Cθ). For the scenario with C = 108 and θ = 10−6 used above, this would lead to the con-
clusion that there was at least a 2-log reduction in the reservoir size. However, this “detection
limit” actually represents a very weak confidence interval, because in repeat sampling, it is
expected that 63% of all draws will from a sample with an infected frequency at this “limit” will
give at least one infected cell.
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